Loading...
OTCMBIOVF
Market cap9.66bUSD
Dec 23, Last price  
27.66USD
1D
-3.35%
1Q
-11.64%
IPO
745.87%
Name

Swedish Orphan Biovitrum AB (publ)

Chart & Performance

D1W1MN
OTCM:BIOVF chart
P/E
43.57
P/S
4.74
EPS
7.01
Div Yield, %
0.00%
Shrs. gr., 5y
3.79%
Rev. gr., 5y
19.34%
Revenues
22.12b
+17.74%
645,285,000936,611,0001,201,099,0001,256,425,0001,140,583,0001,296,973,0001,906,700,0001,910,834,0001,923,161,0002,176,694,0002,606,976,0003,227,867,0005,204,340,0006,510,831,0009,138,892,00014,248,000,00015,261,000,00015,529,000,00018,790,000,00022,123,000,000
Net income
2.41b
-8.68%
-26,491,000176,221,00092,668,00078,984,000-335,361,00032,437,000-104,400,00017,927,000-100,883,000-92,956,000-267,832,00068,393,000809,072,0001,148,612,0002,417,795,0003,304,000,0003,245,000,0002,679,000,0002,638,000,0002,409,000,000
CFO
4.47b
-4.18%
-209,032,000-65,321,000-87,958,000-25,373,000-506,489,00058,885,000-215,100,000102,930,000405,473,000185,389,000233,770,000507,205,000342,857,0001,332,942,0002,090,276,0003,634,000,0005,214,000,0005,470,000,0004,665,000,0004,470,000,000
Earnings
Feb 06, 2025

Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.
URL
https://www.sobi.com/
IPO date
Sep 15, 2006
Employees
1,793
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
22,123,000
17.74%
18,790,000
21.00%
15,529,000
1.76%
Cost of revenue
17,952,000
14,977,000
11,772,000
Unusual Expense (Income)
NOPBT
4,171,000
3,813,000
3,757,000
NOPBT Margin
18.85%
20.29%
24.19%
Operating Taxes
546,000
683,000
616,000
Tax Rate
13.09%
17.91%
16.40%
NOPAT
3,625,000
3,130,000
3,141,000
Net income
2,409,000
-8.68%
2,638,000
-1.53%
2,679,000
-17.44%
Dividends
Dividend yield
Proceeds from repurchase of equity
6,129,000
89,000
BB yield
-7.04%
-0.13%
Debt
Debt current
8,961,000
5,929,000
1,882,000
Long-term debt
11,840,000
3,505,000
9,385,000
Deferred revenue
234,000
Other long-term liabilities
2,861,000
4,146,000
3,834,000
Net debt
19,755,000
7,952,000
10,023,000
Cash flow
Cash from operating activities
4,470,000
4,665,000
5,470,000
CAPEX
(407,000)
(1,477,000)
(370,000)
Cash from investing activities
(21,904,000)
(1,477,000)
(367,000)
Cash from financing activities
17,012,000
(2,991,000)
(4,474,000)
FCF
2,863,000
3,281,000
3,776,000
Balance
Cash
904,000
1,361,000
1,045,000
Long term investments
142,000
121,000
199,000
Excess cash
542,500
467,550
Stockholders' equity
17,315,000
16,314,000
13,324,000
Invested Capital
57,213,000
38,844,500
37,405,450
ROIC
7.55%
8.21%
8.37%
ROCE
6.53%
8.83%
9.06%
EV
Common stock shares outstanding
325,968
312,455
310,729
Price
267.00
23.78%
215.70
16.53%
185.10
11.44%
Market cap
87,033,362
29.14%
67,396,595
17.18%
57,515,929
11.12%
EV
106,788,362
75,348,595
67,604,929
EBITDA
7,340,000
6,232,000
5,763,000
EV/EBITDA
14.55
12.09
11.73
Interest
1,111,000
458,000
419,000
Interest/NOPBT
26.64%
12.01%
11.15%